MULTIPLE MYELOMA

During a Targeted Oncology™ Case-Based Roundtable™ event, Binod Dhakal, MD, MS, and participants discussed which treatment should come next for a patient with relapsed multiple myeloma depending on the patient's ability to travel for care.

During a Targeted Oncology™ Case-Based Roundtable™ event, Carol Ann Huff, MD, discussed the choice of therapy for a patient with relapsed/refractory multiple myeloma. This is is the first of 2 articles based on this event.

Although dosing will continue in iMMagine-1 for patients who responded well to CART-ddBCMA, recruitment has been halted due to to a safety concern.

REGN5459 led to positive responses among patients with multiple myeloma, according to findings from a first-in-human phase 1/2 trial.

Mohamad Mohty, MD, PhD, discusses the growing role of bispecific antibodies for the treatment of multiple myeloma.

A newly authorized phase 1b study will evaluate the safety and efficacy of the continuous delivery of lenalidomide among patients with multiple myeloma.

In part 1 of a 2-part series, Alfred L. Garfall, MD, leads a discussion in the use of adding daratumumab to triplet therapy for patients with multiple myeloma.

Bhagirathbhai R. Dholaria, MBBS, discusses updated findings from the TRIMM-2 trial of talquetamab and daratumumab for the treatment of relapsed/refractory multiple myeloma.

Yael Cohen, MD, discusses the main safety findings from the phase 1/2 RedirecTT-1 trial, which is evaluating the combination of teclistamab-cqyv and talquetamab for the treatment of patients with relapsed/refractory multiple myeloma.

Teclistamab plus talquetamab is the first-ever reported dual-specific bispecific combination in hematologic malignancies, says María-Victoria Mateos, MD, PhD.

Treatment with maintenance daratumumab, with or without pomalidomide, led to a median PFS of 28.5 months in patients with relapsed multiple myeloma after undergoing salvage autologous hematopoietic stem cell transplantation.

Recent studies reported a potential reduction in stem cell yields in patients who were exposed to daratumumab prior to stem cell mobilization.

Interim findings from the phase 2 EMN19 study coupled with the phase 2 LYRA study findings suggest DaraVCD is another option for multiple myeloma with extramedullary disease.

At 2-year follow-up, patients with relapsed/refractory multiple myeloma treated with teclistamab achieved a median progression-free survival of 12.5 months with a median duration of response of 24 months.

In patients with relapsed/refractory multiple myeloma who were previously treated with lenalidomide, the combination of daratumumab, ixazomib, and dexamethasone led to improved overall response rates.

In the second article of this 2-part series, Douglas Sborov, MD, discusses the relevant data that shows the benefit of giving patients with relapsed/refractory multiple myeloma isatuximab as part of a triplet therapy.

Ciltacabtagene autoleucel was recently said to be a new standard-of-care for relapsed or refractory multiple myeloma. Soon, it may be an FDA-approved therapy.

According to Binod Dhakal, MD, ciltacabtagene autoleucel may become a new standard therapy for patients with lenalidomide (Revlimid)-refractory multiple myeloma.

Promising results reported from a study of GC012F in patients with relapsed or refractory multiple myeloma, warrant further research.

Pooled findings from MagnetisMM studies show the elranatamab has early activity in relapsed or refractory multiple myeloma.

MD Anderson Cancer Center's Hans C. Lee, MD has presented promising results from the phase 2 LINKER-MM1 study at ASCO.

The first study of a dual bispecific combination in relapsed or refractory multiple myeloma encourages the investigators.

Now that positive phase 1 results have been reported for PHE855, a phase 2 study of PHE855 is currently underway in patients with relapsed and refractory multiple myeloma.

The FDA is no longer concerned about the safety of MT-0169, and the developer of the agent plans to focus its effort on the extramedullary myeloma population.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, discussed with participants what challenges they face using selinexor in patients with relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.

A comprehensive analysis of the phase 1 LEGEND-2 study shows a correlation between cytokine release syndrome and coagulation disorders inpatient with multiple myeloma treated with CAR T cells.

Prerna Mewawalla, MD, a hematologist at Allegheny Health Network, discusses how her approaches to patients with newly diagnosed multiple myeloma have changed recently based on clinical trial outcomes.

Douglas Sborov, MD, MS, discusses and compares the many triplet therapies for patients who show disease progression after several lines of therapy in this first article of a 2 part series.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, and participants discussed the therapies listed on the National Comprehensive Cancer Network guidelines for patients with relapse after 1 or more prior lines of therapy. This is the first of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sarah M. Larson, MD, discussed the approach to treating a patient with transplant-eligible newly diagnosed multiple myeloma.